M. Coulibaly, Adama Kondé, D. Traoré, O. Bah, Valentin Sagara, B. Maiga
{"title":"莫普提市索宁医院甲胎蛋白在肝癌诊断中的临床价值评价","authors":"M. Coulibaly, Adama Kondé, D. Traoré, O. Bah, Valentin Sagara, B. Maiga","doi":"10.18231/j.ijcbr.2023.028","DOIUrl":null,"url":null,"abstract":"Serum AFP as a poor clinical performance values especially when it comes to deal with the early and AFP-negative diagnostic of HCC. The aim of this work was to assess the contribution of AFP in the diagnosis of HCC. : A total of 95 subjects was enrolled a prospective observational study by consecutive enrolment and divided in two groups. The first group was made up with subjects in whom the diagnosis of HCC had been retained while the second was the control group which was free of HCC. AFP levels were performed by electrochemiluminescence immunoassay on the cobas e411. Data were captured in Excel and analyzed by Ri386 version 4.1.2 binary for macOS 10.13. The Log of median of AFP in HCC subjects was significantly greater than in non HCC subjects 6.91 ng/mL versus 1.43 ng/mL, Wilcoxon < 0.001. At the cut-off of 200 ng/mL, the clinical performances showed an acceptable sensitivity 97.1% CI 95% [93.7 – 100] but a poor specificity 73,8% CI 95% [64.9 – 82.6] and out of the 34 cases of HCC, one case (2.9%) was AFP-negative HCC. our data show an acceptable sensitivity but a weak specificity of AFP as a biomarker for HCC at cut-off 200 ng/mL. This suggests that AFP should be used with other biomarkers mainly for the early and AFP-negative HCC diagnosis.","PeriodicalId":13899,"journal":{"name":"International Journal of Clinical Biochemistry and Research","volume":"18 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Assessment of alpha-fetoprotein clinical performances in the diagnosis of the hepatocellular carcinoma at Sominé DOLO hospital of Mopti\",\"authors\":\"M. Coulibaly, Adama Kondé, D. Traoré, O. Bah, Valentin Sagara, B. Maiga\",\"doi\":\"10.18231/j.ijcbr.2023.028\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Serum AFP as a poor clinical performance values especially when it comes to deal with the early and AFP-negative diagnostic of HCC. The aim of this work was to assess the contribution of AFP in the diagnosis of HCC. : A total of 95 subjects was enrolled a prospective observational study by consecutive enrolment and divided in two groups. The first group was made up with subjects in whom the diagnosis of HCC had been retained while the second was the control group which was free of HCC. AFP levels were performed by electrochemiluminescence immunoassay on the cobas e411. Data were captured in Excel and analyzed by Ri386 version 4.1.2 binary for macOS 10.13. The Log of median of AFP in HCC subjects was significantly greater than in non HCC subjects 6.91 ng/mL versus 1.43 ng/mL, Wilcoxon < 0.001. At the cut-off of 200 ng/mL, the clinical performances showed an acceptable sensitivity 97.1% CI 95% [93.7 – 100] but a poor specificity 73,8% CI 95% [64.9 – 82.6] and out of the 34 cases of HCC, one case (2.9%) was AFP-negative HCC. our data show an acceptable sensitivity but a weak specificity of AFP as a biomarker for HCC at cut-off 200 ng/mL. This suggests that AFP should be used with other biomarkers mainly for the early and AFP-negative HCC diagnosis.\",\"PeriodicalId\":13899,\"journal\":{\"name\":\"International Journal of Clinical Biochemistry and Research\",\"volume\":\"18 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Clinical Biochemistry and Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18231/j.ijcbr.2023.028\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Biochemistry and Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18231/j.ijcbr.2023.028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
血清AFP作为一项较差的临床表现价值,尤其在处理早期及AFP阴性的HCC诊断时。本研究的目的是评估AFP在HCC诊断中的作用。采用连续入组的方法,将95名受试者分为两组,纳入前瞻性观察性研究。第一组由保留HCC诊断的受试者组成,第二组是没有HCC的对照组。用电化学发光免疫法测定cobas e411的AFP水平。数据在Excel中捕获,并在macOS 10.13上使用Ri386 4.1.2二进制文件进行分析。HCC组甲胎蛋白中位对数显著大于非HCC组,前者为6.91 ng/mL,后者为1.43 ng/mL, Wilcoxon < 0.001。在200 ng/mL的临界值下,临床表现为可接受的敏感性为97.1% CI 95%[93.7 - 100],但特异性较差73,8% CI 95%[64.9 - 82.6], 34例HCC中有1例(2.9%)为afp阴性HCC。我们的数据显示AFP作为HCC的生物标志物具有可接受的敏感性,但特异性较弱,临界值为200 ng/mL。这表明AFP应与其他生物标志物联合使用,主要用于早期和AFP阴性的HCC诊断。
Assessment of alpha-fetoprotein clinical performances in the diagnosis of the hepatocellular carcinoma at Sominé DOLO hospital of Mopti
Serum AFP as a poor clinical performance values especially when it comes to deal with the early and AFP-negative diagnostic of HCC. The aim of this work was to assess the contribution of AFP in the diagnosis of HCC. : A total of 95 subjects was enrolled a prospective observational study by consecutive enrolment and divided in two groups. The first group was made up with subjects in whom the diagnosis of HCC had been retained while the second was the control group which was free of HCC. AFP levels were performed by electrochemiluminescence immunoassay on the cobas e411. Data were captured in Excel and analyzed by Ri386 version 4.1.2 binary for macOS 10.13. The Log of median of AFP in HCC subjects was significantly greater than in non HCC subjects 6.91 ng/mL versus 1.43 ng/mL, Wilcoxon < 0.001. At the cut-off of 200 ng/mL, the clinical performances showed an acceptable sensitivity 97.1% CI 95% [93.7 – 100] but a poor specificity 73,8% CI 95% [64.9 – 82.6] and out of the 34 cases of HCC, one case (2.9%) was AFP-negative HCC. our data show an acceptable sensitivity but a weak specificity of AFP as a biomarker for HCC at cut-off 200 ng/mL. This suggests that AFP should be used with other biomarkers mainly for the early and AFP-negative HCC diagnosis.